ABSI vs. TCRX, HARP, ORIC, STRO, TNYA, NRC, OABI, MXCT, LUNA, and NOTV
Should you be buying Absci stock or one of its competitors? The main competitors of Absci include TScan Therapeutics (TCRX), Harpoon Therapeutics (HARP), ORIC Pharmaceuticals (ORIC), Sutro Biopharma (STRO), Tenaya Therapeutics (TNYA), National Research (NRC), OmniAb (OABI), MaxCyte (MXCT), Luna Innovations (LUNA), and Inotiv (NOTV).
TScan Therapeutics (NASDAQ:TCRX) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends.
TScan Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 44.75%. Absci has a consensus price target of $9.25, indicating a potential upside of 117.65%. Given TScan Therapeutics' higher probable upside, analysts clearly believe Absci is more favorable than TScan Therapeutics.
TScan Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500.
TScan Therapeutics has a net margin of -653.50% compared to TScan Therapeutics' net margin of -2,042.01%. TScan Therapeutics' return on equity of -44.60% beat Absci's return on equity.
In the previous week, TScan Therapeutics had 2 more articles in the media than Absci. MarketBeat recorded 8 mentions for TScan Therapeutics and 6 mentions for Absci. TScan Therapeutics' average media sentiment score of 0.91 beat Absci's score of 0.46 indicating that Absci is being referred to more favorably in the news media.
TScan Therapeutics has higher revenue and earnings than Absci. TScan Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 2.8% of TScan Therapeutics shares are owned by insiders. Comparatively, 9.8% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
TScan Therapeutics received 1 more outperform votes than Absci when rated by MarketBeat users. Likewise, 74.19% of users gave TScan Therapeutics an outperform vote while only 53.66% of users gave Absci an outperform vote.
Summary
TScan Therapeutics beats Absci on 9 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
